FTC insists generics ANI and Novitium divest IP before merger
11-11-2021
Teva sues two Indian generics over Huntington’s treatment
06-07-2021
Vivi-o / Shutterstock.com
The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AAM, Generics, reverse payment, California, Pay-for-delay, Ninth Circuit, Kirkland & Elis
